Vertex Pharmaceuticals Incorporated
VRTX
$448.29
$13.123.02%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -13.41% | 9.99% | 4.84% | 59.82% | -29.21% |
| Total Depreciation and Amortization | 128.16% | -54.63% | 4.45% | 6.82% | 127.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -51.71% | 541.24% | -137.30% | -69.21% | 111.93% |
| Change in Net Operating Assets | 125.82% | -733.56% | 212.99% | 50.69% | 52.07% |
| Cash from Operations | 186.77% | -59.88% | 15.68% | 31.04% | 40.08% |
| Capital Expenditure | 10.71% | -46.76% | 30.13% | -257.99% | 56.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -115.21% | -812.50% | 95.51% | -2,143.71% | 97.93% |
| Cash from Investing | -49.91% | -146.24% | 75.85% | -768.28% | 93.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00% | -7.69% | -- | -- |
| Issuance of Common Stock | -50.00% | 583.54% | -83.91% | 194.01% | -51.31% |
| Repurchase of Common Stock | -331.93% | 88.74% | -192.21% | 42.91% | -63.83% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -136.36% | 0.00% | 57.14% | 240.00% | -155.56% |
| Cash from Financing | -597.93% | 93.31% | -230.61% | 48.68% | -73.88% |
| Foreign Exchange rate Adjustments | -652.05% | 278.05% | -107.17% | 87.54% | 164.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 197.93% | 509.36% | -111.53% | 162.01% | 116.75% |